Its interaction with the ligand CCL5 promotes the migration and invasiveness of pancreatic cancer cells, and preclinical studies have shown that pharmacological blockade of CCR5 can significantly reduce tumor growth in murine models of pancreatic cancer [2,75]. This evidence concerns the gene CCR5 and familial pancreatic carcinoma.